The company has launched RAPID U, a training certification program for iSchemaView’s RAPID technology. An imaging standard around the world, RAPID is the platform designed to provide physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke.
2/6/19: The TIMELESS trial is designed to evaluate whether tenecteplase is safe and effective for use in AIS when administered between 4.5 and 24 hours after stroke onset.
8/16/18: he RAPID platform is designed to provide physicians with fast, fully automated, elegant and easy-to-interpret imaging that facilitates clinical decision-making around cerebrovascular disease, such as stroke. Canadian approval comes after iSchemaView’s quality system was certified through the Medical Device Single Audit Program (MDSAP), a global approach to auditing and monitoring the manufacturing of medical devices, in an effort to improve safety and oversight on an international scale.
8/14/18: “Stroke centers want the very best technology to improve patient outcomes, and RAPID’s reputation as the platform of choice for stroke research has accelerated the pace of our growth tremendously,” said Don Listwin, CEO of iSchemaView.
5/15/18: “In my opinion, using RAPID ASPECTS increases the likelihood of getting a reliable ASPECT score, independent of the individual skills and experience of the clinician. This tool is therefore particularly suitable for primary stroke centers with a smaller number of cases,” said Dr. Benjamin Friedrich, docent and physician in the Department of Diagnostic and Interventional Neuroradiology at the Klinikum rechts der Isar in Munich. “Early and reliable information makes it possible to quickly understand the prognosis of a patient.”